Latest Period
Q2 2026
Security Snapshot
Xenon Pharmaceuticals Inc. - Common Stock (XENE) Institutional Ownership
CUSIP: 98420N105
13F Institutional Holders and Ownership History from Q4 2014 to Q2 2026
Institutions Reporting
315
Shares (Excl. Options)
101,110,526
Price
$60.36
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- XENE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 101,110,526
- Total 13F value
- $6,098,672,975
- Portfolio coverage rank
- 0.01%
- Share change
- +923,680
- Value change
- +$63,249,686
- Number of holders
- 315
- Shares outstanding
- 95,032,800
- SEC-reported price per share
- $64.19
- Insider filing price
- $64.19
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- XENE - Xenon Pharmaceuticals Inc. - Common Stock is tracked under CUSIP 98420N105.
- 315 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 289 to 315 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $5,803,238,940 to $6,098,672,975.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 315 institutions filings for Q2 2026.
Security key
98420N105
Latest holder period
Q2 2026
13F holders
315
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
XENE full holder history
Xenon Pharmaceuticals Inc. SEC filings
Xenon Pharmaceuticals Inc. company facts
Xenon Pharmaceuticals Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98420N105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
XENE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 10% | +4% | $674,477,329 | +$24,399,313 | 9,959,795 | +3.8% | FMR LLC | 31 Jul 2026 |
| Avoro Capital Advisors LLC | 6.3% | $328,466,622 | 5,777,777 | Avoro Capital Advisors LLC | 31 Mar 2026 | |||
| BlackRock, Inc. | 6.2% | $148,914,864 | 4,757,709 | BlackRock, Inc. | 30 Jun 2025 | |||
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4.9% | $255,350,473 | 4,491,653 | DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Dec 2025 | |||
| JANUS HENDERSON GROUP PLC | 4.5% | -12% | $237,404,577 | +$13,194,714 | 4,175,982 | +5.9% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.5% | -78% | $96,534,318 | -$226,136,516 | 1,425,492 | -70% | Wellington Management Group LLP | 30 Jun 2026 |
As of 30 Jun 2026, 315 institutional investors reported holding 101,110,526 shares of Xenon Pharmaceuticals Inc. - Common Stock (XENE). This represents 106% of the company’s total 95,032,800 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
72%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 10% | 9,647,998 | -11% | 0.03% | $582,353,159 |
| BlackRock, Inc. | 7.9% | 7,522,482 | +33% | 0.01% | $454,057,014 |
| Avoro Capital Advisors LLC | 6.1% | 5,777,777 | 0% | 3.1% | $348,746,620 |
| Polar Capital Holdings Plc | 4.8% | 4,570,556 | +3.8% | 0.78% | $275,878,760 |
| Driehaus Capital Management LLC | 4.6% | 4,418,557 | -1.6% | 1.5% | $266,704,101 |
| Jupiter Topco LLC | 4.4% | 4,186,519 | 0% | 0.1% | $252,673,122 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.4% | 3,248,219 | +144% | 0.02% | $196,063,000 |
| JPMORGAN CHASE & CO | 2.8% | 2,617,360 | +36% | 0.01% | $157,381,859 |
| Capital International Investors | 2.5% | 2,361,639 | -12% | 0.03% | $142,548,530 |
| T. Rowe Price Investment Management, Inc. | 2.3% | 2,168,581 | +128% | 0.09% | $130,896,000 |
| STATE STREET CORP | 2.1% | 1,969,629 | +14% | 0% | $118,885,244 |
| TWO SIGMA INVESTMENTS, LP | 1.7% | 1,642,848 | +171% | 0.07% | $99,162,305 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.7% | 1,615,696 | 0% | 1% | $97,523,411 |
| Affinity Asset Advisors, LLC | 1.7% | 1,595,000 | -4.8% | 4.7% | $96,274,200 |
| ALLIANCEBERNSTEIN L.P. | 1.6% | 1,562,276 | +11% | 0.03% | $90,846,349 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.6% | 1,507,294 | +7.5% | 0.3% | $90,980,266 |
| FRANKLIN RESOURCES INC | 1.5% | 1,437,712 | +12% | 0.02% | $86,780,296 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.5% | 1,425,492 | -70% | 0.01% | $86,042,698 |
| CITADEL ADVISORS LLC | 1.5% | 1,401,242 | -47% | 0.05% | $84,578,967 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,370,114 | +25% | 0% | $82,692,689 |
| Siren, L.L.C. | 1.4% | 1,318,564 | 0% | 1.6% | $79,588,523 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.4% | 1,290,731 | -3.8% | 0.08% | $77,908,522 |
| Pictet Asset Management Holding SA | 1.2% | 1,187,723 | +75% | 0.07% | $71,645,411 |
| BRAIDWELL LP | 1.2% | 1,131,452 | -15% | 2.5% | $68,294,443 |
| Nuveen, LLC | 1% | 993,126 | +297% | 0.01% | $59,945,086 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
47
Latest
Q2 2026
Rows shown
1-25 of 47
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 101,110,526 | $6,098,672,975 | +$63,249,686 | $60.36 | 315 |
| 2026 Q1 | 100,224,218 | $5,803,238,940 | +$955,207,710 | $58.15 | 289 |
| 2025 Q4 | 84,413,479 | $3,783,396,815 | -$19,907,308 | $44.82 | 245 |
| 2025 Q3 | 84,320,819 | $3,385,181,214 | +$50,763,750 | $40.15 | 218 |
| 2025 Q2 | 83,131,091 | $2,602,180,922 | +$191,395,540 | $31.30 | 206 |
| 2025 Q1 | 76,712,560 | $2,576,157,111 | +$10,187,791 | $33.55 | 206 |
| 2024 Q4 | 76,301,942 | $2,990,887,419 | +$29,910,038 | $39.20 | 209 |
| 2024 Q3 | 74,889,394 | $2,949,541,361 | +$275,979 | $39.37 | 202 |
| 2024 Q2 | 74,169,549 | $2,891,734,051 | +$25,968,930 | $38.99 | 212 |
| 2024 Q1 | 73,488,096 | $3,163,931,600 | +$66,663,770 | $43.05 | 220 |
| 2023 Q4 | 72,058,517 | $3,319,081,625 | +$473,994,183 | $46.06 | 204 |
| 2023 Q3 | 61,366,625 | $2,096,353,515 | +$8,680,142 | $34.16 | 180 |
| 2023 Q2 | 61,306,738 | $2,360,645,061 | +$10,880,022 | $38.50 | 173 |
| 2023 Q1 | 61,134,066 | $2,185,894,799 | +$24,625,634 | $35.79 | 161 |
| 2022 Q4 | 60,466,775 | $2,384,173,156 | +$38,699,727 | $39.43 | 157 |
| 2022 Q3 | 57,955,532 | $2,092,174,527 | +$39,481,459 | $36.10 | 151 |
| 2022 Q2 | 57,007,759 | $1,734,195,451 | +$237,069,658 | $30.42 | 149 |
| 2022 Q1 | 49,043,946 | $1,499,284,580 | +$44,953,028 | $30.57 | 128 |
| 2021 Q4 | 47,689,350 | $1,489,826,062 | +$453,547,589 | $31.24 | 129 |
| 2021 Q3 | 34,071,867 | $521,082,671 | +$347,889 | $15.28 | 113 |
| 2021 Q2 | 33,296,183 | $619,964,580 | +$2,566,015 | $18.62 | 99 |
| 2021 Q1 | 32,964,044 | $590,006,963 | +$88,828,095 | $17.90 | 88 |
| 2020 Q4 | 28,020,659 | $430,912,842 | -$1,905,185 | $15.38 | 79 |
| 2020 Q3 | 27,927,587 | $309,203,900 | -$546,988 | $11.07 | 79 |
| 2020 Q2 | 27,956,934 | $350,580,052 | +$8,434,389 | $12.54 | 78 |